Literature DB >> 26718535

Haemodynamic effects of cardiac resynchronization therapy using single-vein, three-pole, multipoint left ventricular pacing in patients with ischaemic cardiomyopathy and a left ventricular free wall scar: the MAESTRO study.

Fraz Umar1, Robin J Taylor1, Berthold Stegemann2, Howard Marshall3, Sharon Flannigan3, Mauro Lencioni3, Joseph De Bono3, Michael Griffith3, Francisco Leyva4.   

Abstract

AIMS: The clinical response to cardiac resynchronization therapy (CRT) is variable. Multipoint left ventricular (LV) pacing could achieve more effective haemodynamic response than single-point LV pacing. Deployment of an LV lead over myocardial scar is associated with a poor haemodynamic response to and clinical outcome of CRT. We sought to determine whether the acute haemodynamic response to CRT using three-pole LV multipoint pacing (CRT3P-MPP) is superior to that to conventional CRT using single-site LV pacing (CRTSP) in patients with ischaemic cardiomyopathy and an LV free wall scar. METHODS AND
RESULTS: Sixteen patients with ischaemic cardiomyopathy [aged 72.6 ± 7.7 years (mean ± SD), 81.3% male, QRS: 146.0 ± 14.2 ms, LBBB in 14 (87.5%)] in whom the LV lead was intentionally deployed straddling an LV free wall scar (assessed using cardiac magnetic resonance), underwent assessment of LV + dP/dtmax during CRT3P-MPP and CRTSP. Interindividually, the ΔLV + dP/dtmax in relation to AAI pacing with CRT3P-MPP (6.2 ± 13.3%) was higher than with basal and mid CRTSP (both P < 0.001), but similar to apical CRTSP. Intraindividually, significant differences in the ΔLV + dP/dtmax to optimal and worst pacing configurations were observed in 10 (62.5%) patients. Of the 8 patients who responded to at least one configuration, CRT3P-MPP was optimal in 5 (62.5%) and apical CRTSP was optimal in 3 (37.5%) (P = 0.0047).
CONCLUSIONS: In terms of acute haemodynamic response, CRT3P-MPP was comparable an apical CRTSP and superior to basal and distal CRTSP. In the absence of within-device haemodynamic optimization, CRT3P-MPP may offer a haemodynamic advantage over a fixed CRTSP configuration. Published on behalf of the European Society of Cardiology. All rights reserved.
© The Author 2015. For permissions please email: journals.permissions@oup.com.

Entities:  

Keywords:  Cardiac resynchronization therapy; Haemodynamics; Multipoint pacing; Multipolar leads

Mesh:

Year:  2015        PMID: 26718535     DOI: 10.1093/europace/euv396

Source DB:  PubMed          Journal:  Europace        ISSN: 1099-5129            Impact factor:   5.214


  13 in total

Review 1.  Updates in Cardiac Resynchronization Therapy for Chronic Heart Failure: Review of Multisite Pacing.

Authors:  Antonios P Antoniadis; Ben Sieniewicz; Justin Gould; Bradley Porter; Jessica Webb; Simon Claridge; Jonathan M Behar; Christopher Aldo Rinaldi
Journal:  Curr Heart Fail Rep       Date:  2017-10

Review 2.  Electrical manipulation of the failing heart.

Authors:  Valerio Zacà; Theodore Murphy; Mauro Biffi
Journal:  Heart Fail Rev       Date:  2018-11       Impact factor: 4.214

3.  Acute Hemodynamic Effects of Simultaneous and Sequential Multi-Point Pacing in Heart Failure Patients With an Expected Higher Rate of Sub-response to Cardiac Resynchronization Therapy: Results of Multicenter SYNSEQ Study.

Authors:  Maciej Sterliński; Joanna Zakrzewska-Koperska; Aleksander Maciąg; Adam Sokal; Joaquin Osca-Asensi; Lingwei Wang; Vasiliki Spyropoulou; Baerbel Maus; Francesca Lemme; Osita Okafor; Berthold Stegemann; Richard Cornelussen; Francisco Leyva
Journal:  Front Cardiovasc Med       Date:  2022-05-12

4.  Clinical outcome of left ventricular multipoint pacing versus conventional biventricular pacing in cardiac resynchronization therapy: a systematic review and meta-analysis.

Authors:  Feng Hu; Lihui Zheng; Ligang Ding; Zhongpeng Du; Erpeng Liang; Lingmin Wu; Gang Chen; Xiaohan Fan; Yan Yao; Yu Jiang
Journal:  Heart Fail Rev       Date:  2018-11       Impact factor: 4.214

5.  Determinants of LV dP/dtmax and QRS duration with different fusion strategies in cardiac resynchronisation therapy.

Authors:  Hans Henrik Odland; Torbjørn Holm; Lars Ove Gammelsrud; Richard Cornelussen; Erik Kongsgaard
Journal:  Open Heart       Date:  2021-05

6.  Cardiac Resynchronization Therapy Using Quadripolar Versus Non-Quadripolar Left Ventricular Leads Programmed to Biventricular Pacing With Single-Site Left Ventricular Pacing: Impact on Survival and Heart Failure Hospitalization.

Authors:  Francisco Leyva; Abbasin Zegard; Tian Qiu; Edmund Acquaye; Gaetano Ferrante; Jamie Walton; Howard Marshall
Journal:  J Am Heart Assoc       Date:  2017-10-17       Impact factor: 5.501

7.  Multipolar pacing by cardiac resynchronization therapy with a defibrillators treatment in type 2 diabetes mellitus failing heart patients: impact on responders rate, and clinical outcomes.

Authors:  Celestino Sardu; Michelangela Barbieri; Matteo Santamaria; Valerio Giordano; Cosimo Sacra; Pasquale Paolisso; Alessandro Spirito; Raffaele Marfella; Giuseppe Paolisso; Maria Rosaria Rizzo
Journal:  Cardiovasc Diabetol       Date:  2017-06-09       Impact factor: 9.951

8.  Left ventricular scar and the acute hemodynamic effects of multivein and multipolar pacing in cardiac resynchronization.

Authors:  Tom Jackson; Radoslaw Lenarczyk; Maciej Sterlinski; Adam Sokal; Darrell Francis; Zachary Whinnett; Frederic Van Heuverswyn; Marc Vanderheyden; Joeri Heynens; Berthold Stegemann; Richard Cornelussen; Christopher Aldo Rinaldi
Journal:  Int J Cardiol Heart Vasc       Date:  2018-04-10

Review 9.  Cardiac resynchronization therapy in ischemic and non-ischemic cardiomyopathy.

Authors:  Hisashi Yokoshiki; Hirofumi Mitsuyama; Masaya Watanabe; Takeshi Mitsuhashi; Akihiko Shimizu
Journal:  J Arrhythm       Date:  2017-04-21

10.  Cardiac resynchronization therapy: a comparison among left ventricular bipolar, quadripolar and active fixation leads.

Authors:  M Ziacchi; I Diemberger; A Corzani; C Martignani; A Mazzotti; G Massaro; C Valzania; C Rapezzi; G Boriani; M Biffi
Journal:  Sci Rep       Date:  2018-09-05       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.